DC-SIGN as a novel Fc receptor: relationship with structure, function and immunogenicity of therapeutic antibodies

2014 Fiscal Year Final Research Report

• Project/Area Number: 23590214
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Medical pharmacy
• Research Institution: National Institute of Health Sciences
• Principal Investigator: ISHII Akiko 国立医薬品食品衛生研究所, 生物薬品部, 室長 (50291117)
• Co-Investigator(Kenkyū-buntansha): TADA Minoru 国立医薬品食品衛生研究所, 生物薬品部・第三室, 室長 (50506954) ; SUZUKI Takuo 国立医薬品食品衛生研究所, 生物薬品部・第一室, 主任研究官 (10415466)
• Project Period (FY): 2011-04-28 – 2015-03-31
• Keywords: DC-SIGN

Outline of Final Research Achievements

The purpose of this study was to elucidate the role of DC-SIGN, whose involvement in anti-inflammatory action of intravenous immunoglobulin was reported, in structure and function of therapeutic antibodies. SNA-lectin absorbed fraction purified from intravenous immunoglobulin or recombinant IgG prepared by co-transfection of the plasmids encoding IgG and sialyl transferase were used as sialylated IgG. Binding assay using DC-SIGN expressing cells and Surface plasmon resonance spectroscopy were performed. However, binding between sialylated IgG and DC-SIGN was not observed. Other mechanism than direct binding between DC-SIGN and sialylated IgG may be involved in the anti-inflammatory action of therapeutic IVIG.

Free Research Field

生物薬品学